NanoString Technologies Releases Operating Results for Second Quarter of 2022 – Business Wire
Generated Orders for ~ 50 Spatial Biology Instruments, Representing 65% Growth Year-over-Year, Including Orders for More than 25 CosMx Spatial Molecular Imagers
SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter ended June 30, 2022.
Second Quarter Financial Highlights
“NanoString had an excellent second quarter, as our commercial execution continued to improve, and laboratories adopting our solutions drove a 65% year-on-year increase in orders for new spatial biology instruments. Orders for our CosMx Spatial Molecular Imager are ahead of our expectations, and are helping us build a large revenue backlog that we expect will set us up for significant growth in 2023,” said Brad Gray, president & CEO of NanoString. “With complementary instrument platforms, our new AtoMx Spatial Informatics Platform, and blue-chip partnerships, we believe we are ideally positioned to win the spatial biology land-grab currently underway.”
Operational Highlights
Spatial Biology
nCounter
2022 Outlook
The company updated its 2022 outlook, with results expected as follows:
Financial Results
We have elected to present selected non-GAAP, or adjusted, financial measures, including Adjusted EBITDA. These adjusted financial measures are calculated excluding certain items that may make it more challenging to compare our GAAP operating results across periods. Such items may include collaboration revenue, stock-based compensation, depreciation and amortization, or one-time charges such as transaction related fees and expenses or restructuring charges and severance costs. A reconciliation of adjusted financial measures to the nearest comparable GAAP financial measure can be found in the tables at the end of this press release.
(dollars in thousands)
Three Months Ended June 30,
GAAP
Non-GAAP Adjusted
2022
2021
2022
2021
Product and service revenue
$
31,998
$
33,632
$
31,998
$
33,632
Collaboration revenue
221
231
—
—
Total revenue
32,219
33,863
31,998
33,632
Cost of product and service revenue
15,852
15,481
14,756
14,735
Gross Margin
50
%
54
%
54
%
56
%
Research and development
17,346
17,162
14,474
14,469
Selling, general and administrative
36,112
26,855
30,224
21,717
Adjusted EBITDA
N / A
N / A
$
(27,456
)
$
(17,289
)
Non-operating expense, net
(2,148
)
(1,385
)
(2,148
)
(1,385
)
Net loss
$
(39,239
)
$
(27,020
)
$
(29,604
)
$
(18,674
)
Six Months Ended June 30,
GAAP
Non-GAAP Adjusted
2022
2021
2022
2021
Product and service revenue
$
62,839
$
65,026
$
62,839
$
65,026
Collaboration revenue
460
454
—
—
Total revenue
63,299
65,480
62,839
65,026
Cost of product and service revenue
30,630
31,104
28,545
29,762
Gross Margin
51
%
52
%
55
%
54
%
Research and development
34,763
32,225
29,430
27,042
Selling, general and administrative
72,467
53,654
59,621
42,675
Adjusted EBITDA
N / A
N / A
$
(54,757
)
$
(34,453
)
Non-operating expense, net
(4,178
)
(3,229
)
(4,178
)
(3,229
)
Net loss
$
(78,739
)
$
(54,732
)
$
(58,935
)
$
(37,682
)
Supplemental Information
As a supplement to the table above, we have posted to the investor relations section of our website, at www.nanostring.com/Investor Relations/Financials/Quarterly Results, supplemental financial data that include our adjusted financial measures as compared to the nearest comparable GAAP financial measures, for the second quarter and the six months ended June 30, 2022 and for each quarter of and the full year of 2021.
Conference Call
Management will host a conference call today beginning at 1:30 pm PT / 4:30 pm ET to discuss these results and answer questions. Investors and other interested parties can register for the call in advance by visiting https://ige.netroadshow.com/registration/q4inc/11218/nanostring-second-quarter-operating-results/. After registering, an email confirmation will be sent including dial-in details and unique conference call codes for entry. Registration is open throughout the call, but to ensure connection for the full call, registration in advance is recommended. The link to the webcast and audio replay will be made available at the Investor Relations website: www.nanostring.com. A replay of the call will be available beginning August 4, 2022 at 7:30pm ET through midnight ET on August 11, 2022. To access the replay, dial (866) 813-9403 or (929) 458-6194 and reference Conference ID: 426771. The webcast will also be available on our website for one year following the completion of the call.
Non-GAAP, or Adjusted, Financial Information
We believe that the presentation of non-GAAP, or adjusted, financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. Reconciliation of adjusted financial measures to the most directly comparable financial result as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. A reconciliation of adjusted guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding certain expenses that may be incurred in the future. For further information regarding why we believe that these adjusted measures provide useful information to investors, the specific manner in which management uses these measures and some of the limitations associated with the use of these measures, please refer to “Notes Regarding Non-GAAP Financial Information” at the end of this press release.
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three platforms that allow researchers to map the universe of biology. The nCounter® Analysis System, cited in more than 5,800 peer-reviewed publications, offers a way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString’s GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in approximately 130 peer-reviewed publications. The CosMx™ Spatial Molecular Imager, with commercial availability expected in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for demand for our products and growth in our business, future revenue growth, the impact of the COVID-19 pandemic on our operations and future financial performance, the impact of new products and expansion into new markets, the growth trajectory of our nCounter, GeoMx and CosMx franchises, the anticipated launch of new products and technology and our estimated 2022 operating results and our anticipated GAAP and non-GAAP operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; the extent and duration of the impact of the COVID-19 pandemic and adverse conditions in the general domestic and global economic markets; the effects of ongoing litigation; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
The NanoString logo, NanoString, NanoString Technologies, GeoMx, CosMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.
NANOSTRING TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2022
2021
2022
2021
Revenue:
Instruments
$
9,538
$
11,816
$
18,641
$
23,561
Consumables
17,847
17,981
35,315
33,944
Services
4,613
3,835
8,883
7,521
Total product and service revenue
31,998
33,632
62,839
65,026
Collaboration
221
231
460
454
Total revenue
32,219
33,863
63,299
65,480
Costs and expenses:
Cost of product and service revenue
15,852
15,481
30,630
31,104
Research and development
17,346
17,162
34,763
32,225
Selling, general and administrative
36,112
26,855
72,467
53,654
Total costs and expenses (a) (b)
69,310
59,498
137,860
116,983
Loss from operations
(37,091
)
(25,635
)
(74,561
)
(51,503
)
Other income (expense):
Interest income
406
231
557
349
Interest expense
(1,880
)
(1,868
)
(3,763
)
(3,738
)
Other income expense, net
(490
)
334
(707
)
302
Total other expense, net
(1,964
)
(1,303
)
(3,913
)
(3,087
)
Net loss before provision for income taxes
(39,055
)
(26,938
)
(78,474
)
(54,590
)
Provision for income taxes
(184
)
(82
)
(265
)
(142
)
Net loss
$
(39,239
)
$
(27,020
)
$
(78,739
)
$
(54,732
)
Net loss per share, basic and diluted
$
(0.85
)
$
(0.60
)
$
(1.70
)
$
(1.22
)
Weighted average shares used in computing basic and diluted net loss per share
46,427
45,274
46,201
44,973
(a) Includes $6.5 million and $8.0 million of stock-based compensation expense for the three months ended June 30, 2022 and 2021, respectively, and $14.1 million and $15.4 million for the six months ended June 30, 2022 and 2021, respectively.
(b) Includes $2.0 million and $1.4 million of depreciation and amortization expense for the three months ended June 30, 2022 and 2021, respectively, and $3.5 million and $2.9 million for the six months ended June 30, 2022 and 2021, respectively.
NANOSTRING TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
June 30,
2022
December 31,
2021
Assets
Current assets:
Cash and cash equivalents
$
126,027
$
107,068
Short-term investments
146,315
241,821
Accounts receivable, net
31,404
40,130
Inventory, net
41,524
31,486
Prepaid expenses and other
9,427
7,115
Total current assets
354,697
427,620
Property and equipment, net
35,414
27,043
Operating lease right-of-use assets
17,645
19,226
Other assets
5,623
5,592
Total assets
$
413,379
$
479,481
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
16,292
$
14,283
Accrued liabilities
6,999
6,765
Accrued compensation and other employee benefits
13,729
17,466
Customer deposits
1,588
1,278
Deferred revenue and other liabilities, current portion
7,987
7,474
Operating lease liabilities, current portion
5,249
4,889
Total current liabilities
51,844
52,155
Deferred revenue and other liabilities, net of current portion
3,857
3,527
Long-term debt, net
225,877
225,144
Operating lease liabilities, net of current portion
19,136
21,693
Total liabilities
300,714
302,519
Total stockholders’ equity
112,665
176,962
Total liabilities and stockholders’ equity
$
413,379
$
479,481
Notes Regarding Non-GAAP Financial Information. In addition to our results reported in accordance with U.S. generally accepted accounting principles (“GAAP”), we believe certain non-GAAP, or adjusted, measures are useful in evaluating our operating performance. We use adjusted financial measures to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that adjusted financial measures, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, adjusted financial information has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In particular, other companies, including companies in our industry, may calculate similarly titled non-GAAP or adjusted measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our adjusted financial measures as tools for comparison. A reconciliation is provided below for adjusted financial measures to the most directly comparable financial measure stated in accordance with U.S. GAAP. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP, or adjusted, financial measures as analytical tools. Investors are encouraged to review the related U.S. GAAP financial measures and the reconciliation of these adjusted financial measures to their most directly comparable U.S. GAAP financial measure, and not to rely on any single financial measure to evaluate our business.
Expenses excluded from non-GAAP, or adjusted, cost of product and service revenue, research and development expense and selling, general and administrative expense and net loss. We exclude stock-based compensation expense and depreciation and amortization expense, which are non-cash expenses, from certain of our adjusted financial measures because we believe that excluding such items provides meaningful supplemental information regarding operational performance. We exclude certain expenses related to collaborations, recoveries of certain previously remitted state and local taxes, cloud computing arrangement implementation expenses, litigation expenses, and other business development expenses from certain of our adjusted financial measures because such expenses have no direct correlation to the continuing operation of our business as such expenses are non-recurring or non-operating in nature, and therefore we believe excluding these items provides meaningful supplemental information regarding operational performance.
Adjusted EBITDA. Adjusted EBITDA is a non-GAAP financial measure defined as GAAP net loss adjusted for collaboration revenue, stock-based compensation expense, depreciation and amortization, net interest expense, other non-operating expense or income, provision for income tax and other special items as determined by management, including certain expenses related to collaborations, recoveries of certain previously remitted state and local taxes, cloud computing arrangement implementation expenses, litigation expenses, and other business development expenses.
The following tables reflect the reconciliation between GAAP and non-GAAP measures (in thousands).
Three Months Ended June 30,
Six Months Ended June 30,
2022
2021
2022
2021
Net loss – GAAP
$
(39,239
)
$
(27,020
)
$
(78,739
)
$
(54,732
)
Collaboration revenue
(221
)
(231
)
(460
)
(454
)
Stock-based compensation
6,458
7,989
14,125
15,405
Depreciation and amortization
1,961
1,439
3,504
2,880
Interest expense, net
1,474
1,637
3,206
3,389
Other (income) expense, net
490
(334
)
707
(302
)
Provision for income taxes
184
82
265
142
Other business development expenses
44
45
393
115
Litigation expenses
1,237
—
1,930
—
Recovery of certain previously remitted state and local taxes
—
(896
)
—
(896
)
Cloud computing arrangement implementation expenses
156
—
312
—
Adjusted EBITDA – non-GAAP
(27,456
)
(17,289
)
(54,757
)
(34,453
)
Non-operating expense, net
(2,148
)
(1,385
)
(4,178
)
(3,229
)
Net loss – non-GAAP
$
(29,604
)
$
(18,674
)
$
(58,935
)
$
(37,682
)
Three Months Ended June 30,
Six Months Ended June 30,
2022
2021
2022
2021
GAAP Total revenue
$
32,219
$
33,863
$
63,299
$
65,480
Collaboration revenue
(221
)
(231
)
(460
)
(454
)
Non-GAAP Total revenue
$
31,998
$
33,632
$
62,839
$
65,026
GAAP Cost of product and service revenue
$
15,852
$
15,481
$
30,630
$
31,104
Stock-based compensation
(699
)
(585
)
(1,275
)
(1,025
)
Depreciation and amortization
(397
)
(161
)
(810
)
(317
)
Non-GAAP Cost of product and service revenue
$
14,756
$
14,735
$
28,545
$
29,762
GAAP Gross Margin
50
%
54
%
51
%
52
%
Non-GAAP Gross Margin
54
%
56
%
55
%
54
%
GAAP Research and development
$
17,346
$
17,162
$
34,763
$
32,225
Stock-based compensation
(1,818
)
(1,658
)
(3,561
)
(3,041
)
Depreciation and amortization
(1,054
)
(990
)
(1,772
)
(2,027
)
Other business development activities
—
(45
)
—
(115
)
Non-GAAP Research and development
$
14,474
$
14,469
$
29,430
$
27,042
GAAP Selling, general and administrative
$
36,112
$
26,855
$
72,467
$
53,654
Stock-based compensation
(3,941
)
(5,746
)
(9,289
)
(11,339
)
Depreciation and amortization
(510
)
(288
)
(922
)
(536
)
Other business development activities
(44
)
—
(393
)
—
Litigation expenses
(1,237
)
—
(1,930
)
—
Recovery of certain previously remitted state and local taxes
—
896
—
896
Cloud computing arrangements implementation expense
(156
)
—
(312
)
—
Non-GAAP Selling, general and administrative
$
30,224
$
21,717
$
59,621
$
42,675
Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768
Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768